The 2026 Breakthrough Prize awards $3 million each to six scientists for transformative medical discoveries, totaling $18.75 million in recognition. Jean Bennett, Katherine High, and Albert Maguire share one prize for developing the first FDA-approved gene replacement therapy treating Leber congenital amaurosis, a rare inherited blindness affecting the RPE65 gene, with nearly all eligible US patients now treated and maintaining stable vision over a decade later. Stuart Orkin and Swee Lay Thein receive another prize for research identifying BCL11A as the master repressor of fetal hemoglobin, leading to Casgevy, the first CRISPR-based medicine approved for sickle cell disease and beta-thalassemia affecting millions worldwide. Rosa Rademakers and Bryan Traynor are honored for simultaneously discovering the C9orf72 mutation in 2011, explaining about a third of familial ALS and frontotemporal dementia cases in European populations. Additional prizes recognize mathematician Frank Merle for work on nonlinear evolution equations and muon g-2 collaborations spanning six decades at CERN, Brookhaven, and Fermilab.
Story comments
Loading comments…